Mereo BioPharma Group plc (MREO)
NASDAQ: MREO · Real-Time Price · USD
3.580
+0.090 (2.58%)
Nov 20, 2024, 4:00 PM EST - Market closed

Company Description

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally.

It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors.

The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials.

In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), an antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency.

The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; licensing agreement with AstraZeneca; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab.

Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom.

Mereo BioPharma Group plc
Mereo BioPharma Group logo
Country United Kingdom
Founded 2015
Industry Biotechnology
Sector Healthcare
Employees 33
CEO Denise Scots-Knight

Contact Details

Address:
One Cavendish Place, 4th Floor
London, W1G 0QF
United Kingdom
Phone 44 33 3023 7300
Website mereobiopharma.com

Stock Details

Ticker Symbol MREO
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001719714
CUSIP Number 589492107
ISIN Number US5894921072
SIC Code 2834

Key Executives

Name Position
Dr. Denise Vera Scots-Knight Ph.D. Co-Founder, Chief Executive Officer and Executive Director
Charles Edward Sermon Co-Founder, General Counsel, Business Development and Company Secretary
Christine Fox CPA Chief Financial Officer
Dr. John P. Richard M.B.A. Co-Founder and Chief Business Officer
Dr. John A. Lewicki Ph.D. Chief Scientific Officer
Dr. Jackie Parkin Senior Vice President and Therapeutic Head
Alexandra Hughes-Wilson Chief of Patient Access and Commercial Planning
Dr. Suba Krishnan Senior Vice President of Clinical Development
Bo Kara Senior Vice President and Head of Pharmaceutical Development and CMC

Latest SEC Filings

Date Type Title
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 12, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 12, 2024 10-Q Quarterly Report
Nov 12, 2024 8-K Current Report
Sep 12, 2024 144 Filing
Sep 12, 2024 144 Filing
Sep 12, 2024 144 Filing
Sep 12, 2024 144 Filing